Stryker Corp. | StockChase
47
Stryker Corp. (SYK-N)

Last Price Recorded: $157.8800 on 2018-02-22

ON STOCKCHASE SINCE Feb 2002

manufactures orthopedic equipment

biotechnology/pharmaceutical
47
Stryker Corp. (SYK-N)

Last Price Recorded: $157.8800 on 2018-02-22

ON STOCKCHASE SINCE Feb 2002

manufactures orthopedic equipment

biotechnology/pharmaceutical

Stryker Corp.


Signal Opinion Expert
PAST TOP PICK
Stryker Corp.(SYK-N) 

February 14, 2018

(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area.

biotechnology/pharmaceutical

(A Top Pick Mar. 16/17, Up 20%) Like the healthcare equipment space. Aging demographics are positive. They're getting into robots in surgeries, which he views as positive. Expects it to grow in this area.

biotechnology/pharmaceutical
Zachary Curry

Chief Operating Officer & Portfolio Manager, Davis-Rea Ltd....

PricePrice
$156.240
Owned Owned
Yes

HOLD
Stryker Corp.(SYK-N) 

February 12, 2018

Looks okay. Hold it. Worry about it around $140 on the downside. Likes to see a stock fall and then hold, because it shows a dedicated base of shareholders and not a herd mentality. Makes him more confident.

biotechnology/pharmaceutical

Looks okay. Hold it. Worry about it around $140 on the downside. Likes to see a stock fall and then hold, because it shows a dedicated base of shareholders and not a herd mentality. Makes him more confident.

biotechnology/pharmaceutical
Elliott Fishman

Director of U.S. and international equity trading, Trading Services Gro...

PricePrice
$153.660
Owned Owned
Unknown

WEAK BUY
Stryker Corp.(SYK-N) 

December 7, 2017

It is not as diversified as JNJ-N.  He prefers ETFs to capture the theme because you don’t get the risk.

biotechnology/pharmaceutical

It is not as diversified as JNJ-N.  He prefers ETFs to capture the theme because you don’t get the risk.

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Manag...

PricePrice
$151.150
Owned Owned
Unknown

BUY on WEAKNESS
Stryker Corp.(SYK-N) 

October 17, 2017

He likes this company. Anything in the S&P 500, or even the S&P 100, is perfect for him. This closed at $147.29. Has a model price of $140, and the stock is just a little ahead of itself. Would be a buyer on any pullback.

biotechnology/pharmaceutical

He likes this company. Anything in the S&P 500, or even the S&P 100, is perfect for him. This closed at $147.29. Has a model price of $140, and the stock is just a little ahead of itself. Would be a buyer on any pullback.

biotechnology/pharmaceutical
Brian Acker, CA

Chief Executive Officer, President and Chief Inves, Acker Finley Inc....

PricePrice
$148.790
Owned Owned
Unknown

HOLD
Stryker Corp.(SYK-N) 

October 13, 2017

Great company. They are improving their return on capital. Have done everything you could possibly want them to do as a company. However, there is a runaway stock price. If you own it, Hold and look for a better exit.

biotechnology/pharmaceutical

Great company. They are improving their return on capital. Have done everything you could possibly want them to do as a company. However, there is a runaway stock price. If you own it, Hold and look for a better exit.

biotechnology/pharmaceutical
Matt Kacur

President, FSA Financial Scienc...

PricePrice
$146.690
Owned Owned
Unknown

BUY
Stryker Corp.(SYK-N) 

September 14, 2017

Hips, Knees and Ankles.  They are capturing market share.  He is seeing great take up here.

biotechnology/pharmaceutical

Hips, Knees and Ankles.  They are capturing market share.  He is seeing great take up here.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$144.490
Owned Owned
Yes

COMMENT
Stryker Corp.(SYK-N) 

August 25, 2017

Seasonal strength is from the beginning of June until the middle of July and then goes sideways after that.  We reached the end of the seasonal strength in the sector.  You could hold until the next period of seasonal strength or sell it.

biotechnology/pharmaceutical

Seasonal strength is from the beginning of June until the middle of July and then goes sideways after that.  We reached the end of the seasonal strength in the sector.  You could hold until the next period of seasonal strength or sell it.

biotechnology/pharmaceutical
Don Vialoux

Research Analyst, TimingTheMarket.CA &...

PricePrice
$139.880
Owned Owned
Unknown

TOP PICK
Stryker Corp.(SYK-N) 

August 21, 2017

Comparing them to JNJ-N, SYK-N is blowing them out of the water.  They are doing 3D printers to create products where bone can grow back.  Dividend growth is in the 20% range.  (Analysts’ target: US$156.00).

biotechnology/pharmaceutical

Comparing them to JNJ-N, SYK-N is blowing them out of the water.  They are doing 3D printers to create products where bone can grow back.  Dividend growth is in the 20% range.  (Analysts’ target: US$156.00).

biotechnology/pharmaceutical
David Driscoll

President & CEO, Liberty Internationa...

PricePrice
$145.130
Owned Owned
Yes

COMMENT
Stryker Corp.(SYK-N) 

May 9, 2017

The medical device space has done well in healthcare. This goes back to so much money having left biotech. Part of what drives this one is surgical procedure growth. As the population ages, you need to get more surgical procedures. There are some good trends behind this company and it has been executing well. (See Top Picks.)

biotechnology/pharmaceutical

The medical device space has done well in healthcare. This goes back to so much money having left biotech. Part of what drives this one is surgical procedure growth. As the population ages, you need to get more surgical procedures. There are some good trends behind this company and it has been executing well. (See Top Picks.)

biotechnology/pharmaceutical
Jennifer Radman

VP & Sr. Portfolio Manager, Caldwell Investment ...

PricePrice
$134.870
Owned Owned
Unknown

TOP PICK
Stryker Corp.(SYK-N) 

March 16, 2017

This is known for knees and hips, and they have sold millions of knee replacement implants. They’ve recently started using a robot to replace the body parts, giving greater accuracy and lower costs. With the robot, you can only use their parts, making it a closed system. He doesn’t foresee any changes in the US health care act having an effect on this company and their equipment. Dividend yield of 1.3%. (Analysts’ price target is $132.)

biotechnology/pharmaceutical

This is known for knees and hips, and they have sold millions of knee replacement implants. They’ve recently started using a robot to replace the body parts, giving greater accuracy and lower costs. With the robot, you can only use their parts, making it a closed system. He doesn’t foresee any changes in the US health care act having an effect on this company and their equipment. Dividend yield of 1.3%. (Analysts’ price target is $132.)

biotechnology/pharmaceutical
Zachary Curry

Chief Operating Officer & Portfolio Manager, Davis-Rea Ltd....

PricePrice
$131.500
Owned Owned
Yes

BUY
Stryker Corp.(SYK-N) 

March 1, 2017

This is a business that people need to have exposure to. His clients own a similar company, Zimmer Biomet (ZBH-N) which manufactures replacements for hips, knees, and they do stuff for your back, dental. This is a business that unfortunately is going to do well as people age and live longer and wear out their useful parts. Hips and knee replacements is going to grow at a significant rate, and there are only a few companies that manufacture these things.

biotechnology/pharmaceutical

This is a business that people need to have exposure to. His clients own a similar company, Zimmer Biomet (ZBH-N) which manufactures replacements for hips, knees, and they do stuff for your back, dental. This is a business that unfortunately is going to do well as people age and live longer and wear out their useful parts. Hips and knee replacements is going to grow at a significant rate, and there are only a few companies that manufacture these things.

biotechnology/pharmaceutical
Barry Schwartz

CIO & Portfolio Manager, Baskin Wealth Manage...

PricePrice
$131.050
Owned Owned
No

DON'T BUY
Stryker Corp.(SYK-N) 

February 27, 2017

It is an interesting space, but expensive.  Wait until we get clarity on what is happening with Obamacare.  Investors may migrate out of the devices group.

biotechnology/pharmaceutical

It is an interesting space, but expensive.  Wait until we get clarity on what is happening with Obamacare.  Investors may migrate out of the devices group.

biotechnology/pharmaceutical
James Thorne

Sr Portfolio Manager & Chief Capital Markets Strat, Caldwell Investment ...

PricePrice
$128.580
Owned Owned
Unknown

BUY
Stryker Corp.(SYK-N) 

February 22, 2017

This is a long-term Hold. He recently added to his holdings. This is your hip, knees, ankles, feet, prosthetics. You are paying a little bit more for their growth. This is going to be the wave of the future. Feels they are capturing market share.

biotechnology/pharmaceutical

This is a long-term Hold. He recently added to his holdings. This is your hip, knees, ankles, feet, prosthetics. You are paying a little bit more for their growth. This is going to be the wave of the future. Feels they are capturing market share.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$127.290
Owned Owned
Yes

PAST TOP PICK
Stryker Corp.(SYK-N) 

January 12, 2017

(Top Pick Feb 25/16, Up 21.75%) He is not chasing high flying pharma, but the more steady, boring ones that people use more and more as they age.  They grow by acquisition. 

biotechnology/pharmaceutical

(Top Pick Feb 25/16, Up 21.75%) He is not chasing high flying pharma, but the more steady, boring ones that people use more and more as they age.  They grow by acquisition. 

biotechnology/pharmaceutical
Mohsin Bashir

VP Investments, Stone Asset Manageme...

PricePrice
$123.260
Owned Owned
Yes

DON'T BUY
Stryker Corp.(SYK-N) 

November 15, 2016

When it comes to healthcare stocks, you have to differentiate between those pharmaceuticals that have very good margins without any threat to their profit margins, and a stock like this that makes implants. In the field of implants, there has been very little innovation in the last 10 years, and he thinks problems are going to come from both Medicare and Medicaid. Thinks they are going to be pushing prices down, not up, which is a threat to the implant manufacturers.

biotechnology/pharmaceutical

When it comes to healthcare stocks, you have to differentiate between those pharmaceuticals that have very good margins without any threat to their profit margins, and a stock like this that makes implants. In the field of implants, there has been very little innovation in the last 10 years, and he thinks problems are going to come from both Medicare and Medicaid. Thinks they are going to be pushing prices down, not up, which is a threat to the implant manufacturers.

biotechnology/pharmaceutical
John Burke

CEO & CIO, Burke Financial Stra...

PricePrice
$109.740
Owned Owned
Unknown

Showing 1 to 15 of 47 entries
<< < 1 2 3 4 > >>

No Comments.


You must be logged in to comment.

Successfully Saved Company